Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Deggingen – page 63

1 295 clinical trials in Deggingen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Deggingen at a glance
1 295
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 295 trials in Deggingen

Open in trial search

Ovarian cancer

Not recruiting

Phase 3 Study of INCB123667 versus investigator's choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:INCB123667
  • Sponsor:Incyte Corp.

Diabetic retinopathy+1

Not recruiting

A study to evaluate the safety and effectiveness of ANXV in patients with diabetic retinopathy or retinal vein occlusion

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ANXV
  • Sponsor:Annexin Pharmaceuticals AB (publ)

Colitis ulcerative

Not recruiting

A study to evaluate the efficacy and safety of vixarelimab in patients with moderate to severe ulcerative colitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Genentech Inc.

Embolism

Not recruiting

A study to compare how asundexian is absorbed in healthy adults using different formulations and the effect of food for the prevention of blood clots.

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:Asundexian
  • Sponsor:Bayer AG

Efficacy and Safety Evaluation of Odevixibat in Pediatric Biliary Atresia Post-Kasai Hepatoportoenterostomy: A Double-Blind, Randomized, Placebo-Controlled Trial

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Odevixibat
  • Sponsor:Ipsen Pharma

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Moderna Inc.

A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Gilead Sciences Inc.

Bioavailability, Safety and Tolerability of elinzanetant (BAY 3427080) in Healthy Adults for Treatment of Vasomotor Symptoms

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:Elinzanetant
  • Sponsor:Bayer AG

Plasma cell myeloma

Not recruiting

Efficacy and Safety Evaluation of Belantamab Mafodotin Versus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nemtabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Osteosarcoma

Not recruiting

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Cabozantinib
  • Sponsor:Ipsen Innovation

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Deggingen

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on heart failure prevention and managing atrial fibrillation, exploring new therapeutic approaches for cardiac conditions.

  • Heart Failure Prevention Studies
  • Cardioembolic Event Prevention
  • Blood Pressure Management

Research includes evaluation of novel drug combinations and preventive therapies for cardiovascular outcomes.

02 Metabolic Disorders

Comprehensive research on hypertriglyceridemia and Type 2 Diabetes Mellitus, testing new treatments for metabolic conditions.

  • Triglyceride Level Management
  • Diabetes Cardiovascular Outcomes
  • Metabolic Disease Therapies

Studies aim to improve treatment options and long-term patient outcomes in metabolic disorders.

03 Respiratory Medicine

Advanced research targeting Chronic Obstructive Pulmonary Disease, investigating new therapeutic approaches for respiratory conditions.

  • COPD Exacerbation Management
  • Respiratory Disease Treatment
  • Long-term Disease Control

Focus on reducing acute exacerbations and improving quality of life for COPD patients.

04 Other Therapeutic Areas

Studies addressing gout with hyperuricemia and various forms of hypertension, developing targeted treatments.

  • Uric Acid Management
  • Resistant Hypertension Studies
  • Long-term Safety Evaluations

Research aimed at developing effective treatments for complex medical conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.